Scynexis, Inc.

Scynexis, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety, and versatility to defeat even the most insidious fungal diseases. We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest. (NASDAQ: SCYX) The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.

Company Details

Employees
54
Founded
-
Address
1 Evertrust Plaza, Jersey City,new Jersey 07302,united States
Phone
9195448697
Email
Bu****@****xis.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Jersey City, New Jersey
Looking for a particular Scynexis, Inc. employee's phone or email?

Scynexis, Inc. Questions

News

SCYNEXIS to Receive $22 Million Payment from GSK Following MARIO Study Termination - Quiver Quantitative

SCYNEXIS to Receive $22 Million Payment from GSK Following MARIO Study Termination Quiver Quantitative

Biotech Innovator SCYNEXIS to Showcase Drug-Resistant Infection Solutions at H.C. Wainwright Conference - Stock Titan

Biotech Innovator SCYNEXIS to Showcase Drug-Resistant Infection Solutions at H.C. Wainwright Conference Stock Titan

SCYNEXIS to Present Promising Data on SCY-247's Antifungal Activity at TIMM-12 Congress | SCYX Stock News - Quiver Quantitative

SCYNEXIS to Present Promising Data on SCY-247's Antifungal Activity at TIMM-12 Congress | SCYX Stock News Quiver Quantitative

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study - The Manila Times

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study The Manila Times

SCYNEXIS Restarts Key Phase 3 Trial but Faces Payment Dispute with Partner GSK over $30M Milestone - Stock Titan

SCYNEXIS Restarts Key Phase 3 Trial but Faces Payment Dispute with Partner GSK over $30M Milestone Stock Titan

SCYNEXIS announces favourable Phase I data for SCY-247 trial - Clinical Trials Arena

SCYNEXIS announces favourable Phase I data for SCY-247 trial Clinical Trials Arena

SCYNEXIS Doses First Patient in Phase 3 MARIO Study, $10M Milestone Payment Triggered Amid Ongoing Dispute with GSK - Quiver Quantitative

SCYNEXIS Doses First Patient in Phase 3 MARIO Study, $10M Milestone Payment Triggered Amid Ongoing Dispute with GSK Quiver Quantitative

SCYNEXIS Antifungal Drug Cleared by FDA, but GSK Partnership Hits Major Roadblock - Stock Titan

SCYNEXIS Antifungal Drug Cleared by FDA, but GSK Partnership Hits Major Roadblock Stock Titan

SCYNEXIS Announces FDA Approval of BREXAFEMME® - GlobeNewswire

SCYNEXIS Announces FDA Approval of BREXAFEMME® GlobeNewswire

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years - Yahoo Finance

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years Yahoo Finance

GSK makes nice with antifungal partner Scynexis with $22M payment to resolve trial dispute - Fierce Pharma

GSK makes nice with antifungal partner Scynexis with $22M payment to resolve trial dispute Fierce Pharma

Clinical Pharmacology Update: Brexafemme From Scynexis, Inc - Pharmacy Times

Clinical Pharmacology Update: Brexafemme From Scynexis, Inc Pharmacy Times

Breakthrough Against Deadly Superbug: SCYNEXIS's New Drug Shows Promise Against Resistant C. auris Infections - Stock Titan

Breakthrough Against Deadly Superbug: SCYNEXIS's New Drug Shows Promise Against Resistant C. auris Infections Stock Titan

SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets) - Yahoo Finance

SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets) Yahoo Finance

SCYNEXIS Issues a Voluntary Nationwide Recall of - GlobeNewswire

SCYNEXIS Issues a Voluntary Nationwide Recall of GlobeNewswire

Scynexis says GSK on hook for $10M payment after phase 3 Brexafemme trial starts back up - Fierce Pharma

Scynexis says GSK on hook for $10M payment after phase 3 Brexafemme trial starts back up Fierce Pharma

SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years - Yahoo Finance

SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years Yahoo Finance

SCYNEXIS Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

SCYNEXIS Second Quarter 2025 Earnings: Beats Expectations Yahoo Finance

SCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022 - Stock Titan

SCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022 Stock Titan

SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections - Yahoo Finance

SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections Yahoo Finance

Second-Generation Antifungal Aims to Address Invasive Fungal Disease - Contagion Live

Second-Generation Antifungal Aims to Address Invasive Fungal Disease Contagion Live

Brexafemme Recalled Due to Possible Cross Contamination Issue - Medical Professionals Reference

Brexafemme Recalled Due to Possible Cross Contamination Issue Medical Professionals Reference

SCYNEXIS Appoints Christine Coyne as Chief Commercial Officer - citybiz

SCYNEXIS Appoints Christine Coyne as Chief Commercial Officer citybiz

SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in Greater China - Business Wire

SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in Greater China Business Wire

Novel antifungal effective against vulvovaginal candidiasis in phase 3 trials - Healio

Novel antifungal effective against vulvovaginal candidiasis in phase 3 trials Healio

FDA approves ibrexafungerp for reduction in the incidence of RVVC - Contemporary OB/GYN

FDA approves ibrexafungerp for reduction in the incidence of RVVC Contemporary OB/GYN

GSK amends commercial deal with Scynexis as antifungal recall drags into 2024 - Fierce Pharma

GSK amends commercial deal with Scynexis as antifungal recall drags into 2024 Fierce Pharma

FDA grants ibrexafungerp sNDA priority review for RVVC - Contemporary OB/GYN

FDA grants ibrexafungerp sNDA priority review for RVVC Contemporary OB/GYN

GSK manufacturing review prompts Scynexis to pull Brexafemme, halt trials over contamination concerns - Fierce Pharma

GSK manufacturing review prompts Scynexis to pull Brexafemme, halt trials over contamination concerns Fierce Pharma

Scynexis plans to cut 40% of staff and license its approved antifungal in pivot to R&D - Fierce Pharma

Scynexis plans to cut 40% of staff and license its approved antifungal in pivot to R&D Fierce Pharma

Scynexis: Update Following Restructuring Of GSK Deal (NASDAQ:SCYX) - Seeking Alpha

Scynexis: Update Following Restructuring Of GSK Deal (NASDAQ:SCYX) Seeking Alpha

Eyeing $600M in peak sales, Scynexis preps ambitious launch for antifungal Brexafemme - Fierce Pharma

Eyeing $600M in peak sales, Scynexis preps ambitious launch for antifungal Brexafemme Fierce Pharma

Ex- Medicines Company executive lands at Scynexis - Fierce Biotech

Ex- Medicines Company executive lands at Scynexis Fierce Biotech

Scynexis partners with Amplity Health to commercialize antifungal - The Pharma Letter

Scynexis partners with Amplity Health to commercialize antifungal The Pharma Letter

Scynexis antifungal drug secures FDA nod; first approval in new class in 20 years - MedCity News

Scynexis antifungal drug secures FDA nod; first approval in new class in 20 years MedCity News

SCYNEXIS (SCYX) Stock Price, News & Analysis - MarketBeat

SCYNEXIS (SCYX) Stock Price, News & Analysis MarketBeat

FDA approves ibrexafungerp tablet for recurrent vulvovaginal candidiasis - Medical Dialogues

FDA approves ibrexafungerp tablet for recurrent vulvovaginal candidiasis Medical Dialogues

Top Scynexis, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant